Diacetyl, a toxic molecule found in microwave popcorn flavoring and linked to lung injuries in factory workers, might play an important role in microbial lung infections in cystic fibrosis patients.
The FDA has approved a supplemental New Drug Application for Kalydeco (ivacaftor) for use in eight additional mutations that cause cystic fibrosis.
Normal physiological changes of the mother during pregnancy have the potential to exacerbate preexisting cardiorespiratory conditions or lead to new disorders.
Electromed Inc has received FDA market clearance for its SmartVest SQL Airway Clearance System. SQL delivers high frequency chest wall oscillation (HFCWO) to promote airway clearance, improve bronchial drainage, and enhance mucus transport.
The $80,000 grant will support research into the mechanisms underlying Hermansky-Pudlak syndrome (HPS), a rare inherited disease which affects a number of organs, including the lungs.
KaloBios Pharmaceuticals was awarded an orphan drug designation by the FDA for KB001-A, which is being developed to prevent or treat a common opportunistic gram negative bacterium, Pseudomonas aeruginosa (Pa).
Clinical pulmonary function testing using spirometry is an essential tool for the diagnosis and management of cystic fibrosis, but new research and new technology advancements suggest home spirometry could soon become an efficient alternative.
Hill-Rom received marketing approval from the FDA for the MetaNeb 4.0 System, which will begin shipping in June.
Mycobacterium abscessus, a multidrug-resistant bacteria that causes progressive lung damage, can be transmitted person-to-person in cystic fibrosis patients. The research findings are forcing health officials to rethink infection control measures.
A new dry powder inhalant from Novartis, TOBI Podhaler, has been approved for CF patients with Pseudomonas aeruginosa (Pa) bacteria in the lungs. The drug is the first and only dry powder treatment on the market and reduces treatment time by 70%.